1239460-75-3 Usage
General Description
5-bromo-8-(trifluoromethyl)quinoline is a chemical compound with the molecular formula C11H5BrF3N. It is a derivative of quinoline, which is a heterocyclic aromatic compound. The presence of a bromine atom and a trifluoromethyl group in this compound makes it useful in various chemical reactions and pharmaceutical applications. It is commonly used in the synthesis of pharmaceutical drugs and agrochemicals. The compound is also known for its fluorescence properties, which make it useful in the field of materials science and fluorescence imaging. Additionally, it has been studied for its potential antimicrobial and antiviral properties. Overall, 5-bromo-8-(trifluoromethyl)quinoline is an important chemical compound with a wide range of potential applications across different scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1239460-75-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,9,4,6 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1239460-75:
(9*1)+(8*2)+(7*3)+(6*9)+(5*4)+(4*6)+(3*0)+(2*7)+(1*5)=163
163 % 10 = 3
So 1239460-75-3 is a valid CAS Registry Number.
1239460-75-3Relevant articles and documents
Transition metal-free direct C–H trifluoromethyltion of (hetero)arenes with Togni's reagent
Chen, Xiaoyu,Ding, Licheng,Li, Linlin,Li, Jingya,Zou, Dapeng,Wu, Yangjie,Wu, Yusheng
, (2020)
A new transition-metal-free direct C–H trifluoromethylation reaction of (hetero)arenes with Togni's reagent was developed. This transformation proceeded smoothly under mild conditions and exhibited good tolerance of many synthetically relevant functional groups. It provided an alternative approach for the synthesis of trifluoromethylated (hetero)arenes.
INHIBITORS OF JUN N-TERMINAL KINASE
-
Page/Page column 101, (2010/08/18)
The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.